Equities

Allergy Therapeutics PLC

Allergy Therapeutics PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)5.40
  • Today's Change-0.20 / -3.57%
  • Shares traded913.44k
  • 1 Year change+280.28%
  • Beta1.9205
Data delayed at least 20 minutes, as of Nov 08 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of GBP
(except for per share items)
Fiscal data as of Jun 30 2023202320222021
ASSETS
Cash And Short Term Investments152140
Total Receivables, Net5.065.914.62
Total Inventory121111
Prepaid expenses2.034.561.60
Other current assets, total----0.53
Total current assets344258
Property, plant & equipment, net232020
Goodwill, net3.353.353.34
Intangibles, net1.791.691.41
Long term investments4.875.335.76
Note receivable - long term------
Other long term assets------
Total assets677388
LIABILITIES
Accounts payable4.094.282.90
Accrued expenses121114
Notes payable/short-term debt000
Current portion long-term debt/capital leases1.802.271.76
Other current liabilities, total0.180.160.03
Total current liabilities191818
Total long term debt348.269.42
Total debt361111
Deferred income tax0.450.410.41
Minority interest------
Other liabilities, total118.4611
Total liabilities653540
SHAREHOLDERS EQUITY
Common stock0.690.650.65
Additional paid-in capital119113113
Retained earnings (accumulated deficit)(118)(76)(65)
Treasury stock - common------
Unrealized gain (loss)1.501.071.07
Other equity, total(0.73)(0.92)(1.19)
Total equity2.073849
Total liabilities & shareholders' equity677388
Total common shares outstanding1,7171,7171,416
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.